ClinicalTrials.gg
CompletedNCT00508495Updated Aug 11, 2011

Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-Containing Solutions in Post-Surgical Hip Replacement Pain

A Phase 3 interventional study of Paracetamol (acetaminophen) and Paracetamol 1% solution in Pain, Postoperative, sponsored by Baxter Healthcare Corporation. Completed at 8 sites in Hungary. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-11.

Sponsored by Baxter Healthcare Corporation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Enrollment
33rd of 118
148 · median 90
Started
2007
with 2 others
Phase 3
20 of 118
1 open now
Registered
5th of 118
by date
Lead sponsor
2 of 118
Baxter Healthcare Corporation

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 33rd largest by enrollment, is one of 3 that started in 2007, is one of 20 in phase 3, and was the 5th registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

The aim of the study is to evaluate the therapeutic efficacy, safety and local tolerability of two different paracetamol-containing solutions in postoperative total hip replacement. They will be compared to placebo (a dummy treatment which contains no active ingredient).

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • pain, postoperative
  • replacement, total hip
  • total hip replacement
  • arthroplasty, replacement, hip
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , II or III and scheduled for elective total hip replacement, using a standard approach and a cemented implant.
  • Moderate or severe pain within 4 hours after stopping the PCA in the morning of the first post-operative day.

Exclusion criteria

Exclusion Criteria:

  • Another acute or chronic painful physical condition
  • Use of any other analgesics (within 24 hours), sedatives, or narcotic drugs as well as microsomal enzyme inducers
  • Inability to use and understand Visual Analog Scale and Verbal Rating Score
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Test drug

    Drug: Paracetamol 1% solution

  • Active comparator
    Reference drug

    Drug: Paracetamol (acetaminophen)

  • Placebo comparator
    Placebo

    Drug: 0.9% sodium chloride solution

Interventions

  • DrugAcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Four 100 mL, 15 min IV infusions at six hour intervals

    Also known as: Perfalgan

  • DrugAcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Four 100 mL, 15 min IV infusions at six hour intervals

  • Drug0.9% sodium chloride solution

    Four 100 mL, 15 min IV infusions at six hour intervals

    Also known as: Normal saline solution

06

What researchers measure

Primary outcomes

  1. Amount of PCA-administered morphine consumed during first six hours of study drug treatment

    Time frame: 6 hours from first (of four) study drug doses

07

Study locations

8 sites
  • Semmelweis Egyetem Ortopédiai Klinika
    Budapest, Hungary
  • Réthy Pál Kórház-Rendelőintézet
    Békéscsaba, Hungary
  • Esztergom Város Önkormányzat Vaszary Kolos Kórháza
    Esztergom, Hungary
  • Petz Aladár Megyei Oktató Kórház
    Győr, Hungary
  • Bács-Kiskun Megyei Önkormányzat Kórháza
    Kecskemet, Hungary
  • SZTE ÁOK Ortopédiai Klinika
    Szeged, Hungary
  • Fejér Megyei Szent György Kórház
    Szekesfehervar, Hungary
  • Tolna Megyei Önkormányzat Balassa János Kórháza
    Szekszárd, Hungary
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 30, 2007
Start
Aug 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Aug 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00508495
Collaborators
MDS Pharma Services
First posted
Jul 30, 2007
Start date
Aug 2007
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Aug 11, 2011

Study contacts

Keyvan Tadjalli Mehr, MD, MSc
study director · Baxter Deutschland GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion